UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

The Journal of clinical investigation, 2010-07, Vol.120 (7), p.2406-2413

2010

Volltextzugriff (PDF)

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

Nature medicine, 2012-07, Vol.18 (7), p.1052-1059

2012

Volltextzugriff (PDF)

Targeting the Phosphatidylinositol 3‐Kinase Signaling Pathway in Breast Cancer

The oncologist (Dayton, Ohio), 2011-01, Vol.16 (4), p.404-414

2011

Volltextzugriff (PDF)

A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance

Clinical cancer research, 2011-04, Vol.17 (7), p.2024-2034

2011

Volltextzugriff (PDF)

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancers

Cancer, 2010-11, Vol.116 (22), p.5161-5167

2010

Volltextzugriff (PDF)

Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy

Journal of clinical oncology, 2012-09, Vol.30 (26), p.3287-3296

2012

Volltextzugriff (PDF)

Metformin: A Therapeutic Opportunity in Breast Cancer

Clinical cancer research, 2010-03, Vol.16 (6), p.1695-1700

2010

Volltextzugriff (PDF)

Triple‐Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer

The oncologist (Dayton, Ohio), 2011-12, Vol.16 (12), p.1675-1683

2011

Volltextzugriff (PDF)

Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors

Journal of clinical oncology, 2012-02, Vol.30 (6), p.593-599

2012

Volltextzugriff (PDF)

Earlier age of onset of BRCA mutation‐related cancers in subsequent generations

Cancer, 2012-01, Vol.118 (2), p.321-325

2012

Volltextzugriff (PDF)

Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer

Journal of clinical oncology, 2009-07, Vol.27 (20), p.3297-3302

2009

Volltextzugriff (PDF)

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

Journal of clinical oncology, 2008-03, Vol.26 (8), p.1275-1281

2008

Volltextzugriff (PDF)

Primary angiosarcomas of the breast

Cancer, 2007-07, Vol.110 (1), p.173-178

2007

Volltextzugriff (PDF)

PD-L1 expression in triple-negative breast cancer

Cancer immunology research, 2014-04, Vol.2 (4), p.361-370

2014

Volltextzugriff (PDF)

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer

Molecular cancer therapeutics, 2011-06, Vol.10 (6), p.1093-1101

2011

Volltextzugriff (PDF)

Effect of metformin on survival outcomes in diabetic patients with triple receptor‐negative breast cancer

Cancer, 2012-03, Vol.118 (5), p.1202-1211

2012

Volltextzugriff (PDF)

High ERK Protein Expression Levels Correlate with Shorter Survival in Triple‐Negative Breast Cancer Patients

The oncologist (Dayton, Ohio), 2012-06, Vol.17 (6), p.766-774

2012

Volltextzugriff (PDF)

High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller

Journal of clinical oncology, 2009-12, Vol.27 (34), p.5700-5706

2009

Volltextzugriff (PDF)

Trends for Inflammatory Breast Cancer: Is Survival Improving?

The oncologist (Dayton, Ohio), 2007-08, Vol.12 (8), p.904-912

2007

Volltextzugriff (PDF)

Reverse‐Phase Protein Array for Prediction of Patients at Low Risk of Developing Bone Metastasis From Breast Cancer

The oncologist (Dayton, Ohio), 2014-09, Vol.19 (9), p.909-914

2014

Volltextzugriff (PDF)

Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes

Clinical cancer research, 2009-12, Vol.15 (23), p.7381-7388

2009

Volltextzugriff (PDF)

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor—positive breast cancer

Proceedings of the National Academy of Sciences - PNAS, 2010-06, Vol.107 (22), p.10208-10213

2010

Volltextzugriff (PDF)

Phase II study of gefitinib in patients with advanced salivary gland cancers

Head & neck, 2015-05, Vol.37 (5), p.644-649

2015

Volltextzugriff (PDF)

Concordance of genomic alterations between primary and recurrent breast cancer

Molecular cancer therapeutics, 2014-05, Vol.13 (5), p.1382-1389

2014

Volltextzugriff (PDF)

Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other Factors

Journal of clinical oncology, 2006-03, Vol.24 (7), p.1037-1044

2006

Volltextzugriff (PDF)

1 – 25 von 260

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(255)
Mit Volltextzugriff
(246)

Publikationsform

Artikel
(260)

Sprache

Englisch
(260)
Japanisch
(52)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(62)
Cancer
(32)
Cancer Research
(19)
Clinical Cancer Research
(18)
Clinical Breast Cancer
(13)
The Oncologist
(13)
The oncologist
(12)
Breast Cancer Research And Treatment
(6)
Breast Cancer Research : Bcr
(5)
The Breast Journal
(5)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

Targeting the Phosphatidylinositol 3‐Kinase Signaling Pathway in Breast Cancer

A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancers

Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy

Metformin: A Therapeutic Opportunity in Breast Cancer

Triple‐Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer

Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors

Earlier age of onset of BRCA mutation‐related cancers in subsequent generations

Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

Primary angiosarcomas of the breast

PD-L1 expression in triple-negative breast cancer

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer

Effect of metformin on survival outcomes in diabetic patients with triple receptor‐negative breast cancer

High ERK Protein Expression Levels Correlate with Shorter Survival in Triple‐Negative Breast Cancer Patients

High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller

Trends for Inflammatory Breast Cancer: Is Survival Improving?

Reverse‐Phase Protein Array for Prediction of Patients at Low Risk of Developing Bone Metastasis From Breast Cancer

Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor—positive breast cancer

Phase II study of gefitinib in patients with advanced salivary gland cancers

Concordance of genomic alterations between primary and recurrent breast cancer

Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other Factors

Suchergebnisse filtern